COVID-19: Vaccine-induced immune thrombotic thrombocytopenia.
Eur J Haematol
; 109(6): 619-632, 2022 Dec.
Статья
в английский
| MEDLINE | ID: covidwho-2256225
ABSTRACT
In late February 2021, a prothrombotic syndrome was encountered for the first time in some of the recipients of ChAdOx1 CoV-19 vaccine (AstraZeneca, University of Oxford, and Serum Institute of India). Since the hallmark of this syndrome is the development of thrombocytopenia and/or thrombosis between 4 and 42 days after receiving a COVID-19 vaccine, it was named vaccine-induced immune thrombotic thrombocytopenia (VITT). Other names include "vaccine-induced prothrombotic immune thrombocytopenia" and "thrombosis with thrombocytopenia syndrome" by the Centers for Disease Control and the Food and Drug Administration (FDA). VITT appears similar to heparin-induced thrombocytopenia in that "platelet activating" autoantibodies are produced in both these conditions due to prior exposure of COVID-19 vaccine and heparin respectively, in turn causing thrombotic complications and consumptive thrombocytopenia. In this article, recent advances in the understanding of pathobiology, clinical features, investigative work-up, and management of VITT are reviewed.
ключевые слова
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
Thrombocytopenia
/
Thrombosis
/
Purpura, Thrombocytopenic, Idiopathic
/
COVID-19 Vaccines
/
COVID-19
Тип исследования:
Диагностическое исследование
/
Прогностическое исследование
Темы:
Длинный Ковид
/
Вакцина
Пределы темы:
Люди
Язык:
английский
Журнал:
Eur J Haematol
Тематика журнала:
Гематология
Год:
2022
Тип:
Статья
Аффилированная страна:
Ejh.13855
Документы, близкие по теме
MEDLINE
...
LILACS
LIS